The anticancer effects of PCAIs in pancreatic cancer cells involve MAPK and PI3K/AKT pathways hyperactivation
Oncotarget · 03.06.2026 · 17 (1) · 268-290
DOI: 10.18632/oncotarget.28879 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncotarget, erschienen am 03.06.2026. Verfasst von Kweku Ofosu-Asante und 3 weiteren Autor:innen. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Proto-Oncogene Proteins c-akt, Phosphatidylinositol 3-Kinases, Antineoplastic Agents. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIMHD NIH HHS.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Förderung
- NCI NIH HHS
- NIMHD NIH HHS
Zitieren
APA
Ofosu-Asante, K., Lazarte, J. M. S., Burra, A. G., & Lamango, N. S. (2026). The anticancer effects of PCAIs in pancreatic cancer cells involve MAPK and PI3K/AKT pathways hyperactivation. Oncotarget, 17(1), 268-290. https://doi.org/10.18632/oncotarget.28879
Vancouver
Ofosu-Asante K, Lazarte JMS, Burra AG, Lamango NS. The anticancer effects of PCAIs in pancreatic cancer cells involve MAPK and PI3K/AKT pathways hyperactivation. Oncotarget. 2026;17(1):268-290. doi:10.18632/oncotarget.28879
BibTeX
@article{OfosuAsante2026,
author = {Ofosu-Asante, Kweku and Lazarte, Jassy Mary S and Burra, Amarender Goud and Lamango, Nazarius S},
title = {The anticancer effects of PCAIs in pancreatic cancer cells involve MAPK and PI3K/AKT pathways hyperactivation},
journal = {Oncotarget},
year = {2026},
volume = {17},
number = {1},
pages = {268--290},
doi = {10.18632/oncotarget.28879}
}
EUVIMED